ArticleEpidemiology and infection2022
Drug resistance characteristics of
Article in Epidemiology and infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trends and Characteristics of Drug-Resistant Tuberculosis: A Five-Year Study at a Major Specialized Hospital in Guizhou, China (2018-2023).Infection and drug resistance · 2026Article
- Drug resistance patterns among tuberculosis patients at a tuberculosis designated hospital in Yunnan: a retrospective analysis of the 2013-2022 period.BMC infectious diseases · 2025Article
- Drug resistance among students with pulmonary tuberculosis: a study based on screening in Henan, China.BMC infectious diseases · 2025Article
- Sentinel-Site-Based Surveillance ofAntibiotics (Basel, Switzerland) · 2025Article
- Magnitude, predictors, and trends of multidrug-resistant tuberculosis among tuberculosis patients at Debre Markos, Northwest, Ethiopia: a five-year retrospective study.JAC-antimicrobial resistance · 2025Article
- Comparative genomic and antimicrobial resistance profiles ofFrontiers in microbiology · 2025Article
- Antimicrobial resistance and genomic investigation ofFrontiers in microbiology · 2024Article
- Mycobacterium tuberculosis and its clever approaches to escape the deadly macrophage.World journal of microbiology & biotechnology · 2023Review
- Assessing the influencing factors of out-of-pocket costs on tuberculosis in Sichuan Province: a cross-sectional study.BMC public health · 2023Article
- Microbiota and mycobiota in bronchoalveolar lavage fluid of silicosis patients.Journal of occupational medicine and toxicology (London, England) · 2023Article
- [Epidemiological Characteristics and Drug Resistance of Microbial Pathogens of Patients With Silicosis Combined With Pulmonary Infection].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2023Article
- Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now.Cureus · 2023Review
- Analysis of Drug-Resistant Tuberculosis in Children in Shenyang, China, 2017-2021.Infection and drug resistance · 2023Article
- Treatment outcome and its associated factors among HIV-MTB co-infected patients in Sichuan, China: A retrospective study.Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the drug resistance of Mycobacterium tuberculosis isolates from patients with tuberculosis (TB) and HIV, and those diagnosed with only TB in Sichuan, China. TB isolates were obtained from January 2018 to December 2020 and subjected to drug susceptibility testing (DST) to 11 anti-TB drugs and to GeneXpert MTB/RIF testing. The overall proportion of drug-resistant TB (DR-TB) isolates was 32.1% (n = 10 946). HIV testing was not universally available for outpatient TB cases, only 29.5% (3227/10 946) cases had HIV testing results. The observed proportion of multidrug-resistant TB (MDR-TB) isolates was almost double than that of the national level, with approximately 1.5% and 0.1% of the isolates being extensively drug resistant and universally drug resistant, respectively. The proportions of resistant isolates were generally higher in 2018 and 2019 than in 2020. Furthermore, the sensitivities of GeneXpert during 2018-2020 demonstrated a downward trend (80.9, 95% confidence intervals (CI) 76.8-85.0; 80.2, 95% CI 76.4-84.1 and 75.4, 95% CI 70.7-80.2, respectively). Approximately 69.0% (7557/10 946) of the TB cases with DST results were subjected to GeneXpert detection. Overall, the DR-TB status and the use of GeneXpert in Sichuan have improved, but DR-TB challenges remain. HIV testing for all TB cases is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.